Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma

Next Previous
Trial Profile

Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs CAR-T cell therapies (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top